证券代码：301602 证券简称：超研股份 公告编号：2025-038 汕头市超声仪器研究所股份有限公司 2025 年半年度募集资金存放、管理与实际使用情况的专项报 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 1、实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有 限公司首次公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意 注册，汕头市超声仪器研究所股份有限公司（以下简称"公司"）已完成 首次公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元， 募集资金总额为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不含税），公司实际募集资金净额为人民币 384,363,201.32 元，募集 资金已于 2025 年 1 月 17 日划至公司指定账户。华兴会计师事务所（特殊 普通合伙）对公司本次公开发行股票的资金到位情况进行了审验，并于 2025 年 1 月 17 日出具了《验资报告》（华兴验字〔2025〕210 ...

汕头市超声仪器研究所股份有限公司 董事、高级管理人员自律守则 第一条 董事、高级管理人员是汕头市超声仪器研究所股份有限公司（以下 简称"公司"）重要机构的组成人员，其行为活动直接影响到公司、股东以及他 人的利益，及社会经济秩序。根据有关法律、法规和规范性文件和《汕头市超声 仪器研究所股份有限公司章程》（以下简称"公司章程"）的规定，特制定本守 则。 第二条 董事、高级管理人员应积极学习专业技术、管理业务知识及社会主 义市场经济知识。 第三条 董事、高级管理人员应当遵守法律和公司章程，忠实履行职责，全 心全意处理公司事务，维护公司利益，对公司忠诚，不得利用在公司的地位、职 位、职权和内幕信息为自己谋私利。 第四条 董事、高级管理人员不得利用职权收受贿赂或者其他非法收入，不 准把经营、管理活动中收取的折扣、中介费、礼金据为己有。 第五条 董事、高级管理人员不得挪用公司资金。 第六条 董事和高级管理人员不得将公司资产以其个人名义或者他人名义 开立账户存储。 第七条 公司董事和高级管理人员负有忠实义务，应当采取措施避免自身利 益与公司利益冲突，不得利用职权牟取不正当利益，维护公司利益；公司董事和 高级管理人员负有勤勉 ...

一、修订《公司章程》的情况 为全面贯彻落实《中华人民共和国公司法（2023 年修订）》等法律法规要 求，进一步规范公司运作机制，提升公司治理水平，根据《上市公司章程指引（2025 年修订）》《深圳证券交易所创业板股票上市规则（2025 年修订）》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2025 年 修订）》等最新法律法规、规范性文件的要求，拟对《汕头市超声仪器研究所股 份有限公司章程》进行修订，具体修订情况如下： | 修订前 | 修订后 | | --- | --- | | 第五条 公司住所：汕头市金砂路 77 号（另一 | 第五条 公司住所：汕头市金砂路 77 号（另一经营 | | 经营场所：汕头市龙江路 3 号）。 | 场所：汕头市龙江路 3 号）。 | | | 邮政编码：515000 | | 第八条 公司董事长为公司的法定代表人，其产 | 第八条 公司董事长为公司的法定代表人，其产生 | | 生及变更方式按照本章程相关规定执行。 | 及变更方式按照本章程相关规定执行。 | | 担任法定代表人的董事长辞任的，视为同时辞去 | 担任法定代表人的董事长辞任的，视为同时辞去法 ...

单位：万元 法定代表人：李德来 主管会计工作负责人: 陈小波 会计机构负责人：陈小波 | | | 占用方与 上市公司 | 上市公司核 | 2025 年期初占 | 2025 半年度 占用累计发 | 2025 年半 年度占用 | 2025 年半年度 | 2025 年半年期 | 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 的关联关 | 算的会计科 | 用资金余额 | 生金额（不含 | 资金的利 | 偿还累计发生 | 末占用资金余 | 因 | 占用性质 | | | | 系 | 目 | | 利息） | 息(如有) | 金额 | 额 | | | | 控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人 | | | | | | | | | | | | 及其附属企业 | | | | | | | | | | | | 小 ...

汕头市超声仪器研究所股份有限公司 2025 年半年度报告全文 证券代码：301602 证券简称：超研股份 公告编号：2025-035 汕头市超声仪器研究所股份有限公司 2025 年半年度报告 2025 年 8 月 1 汕头市超声仪器研究所股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人李德来、主管会计工作负责人陈小波及会计机构负责人(会计 主管人员)陈小波声明：保证本半年度报告中财务报告的真实、准确、完整。 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议 | 未亲自出席董事 | 未亲自出席董 | | 被委托人姓 | | --- | --- | --- | --- | | 姓名 | 事职务 | 未亲自出席会议原因 | 名 | | 吴宏豪 | 董事 | 因公务，无法到场 | 周宏策 | 本报告中所涉及的未来计划、发展战略等前瞻性陈述均不构成公司对投 资者的实质承诺，敬请广大投资者及相关人士均应当对此保持足够的风险认 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Chao Yan Co., Ltd. in the medical device industry, showcasing its financial metrics and competitive standing [1][2] - As of August 25, Chao Yan Co., Ltd. closed at 28.18 yuan, with a rolling price-to-earnings (PE) ratio of 76.26, significantly higher than the industry average of 55.91 [1][2] - The company's total market capitalization is reported at 12.07 billion yuan, ranking it 96th in the medical device sector based on PE ratio [1][2] Group 2 - The company reported a revenue of 98.43 million yuan for Q1 2025, reflecting a year-on-year increase of 28.69%, and a net profit of 39.32 million yuan, up 47.70% year-on-year [1] - The gross profit margin for the company stands at 73.83%, indicating strong profitability in its operations [1] - Chao Yan Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a well-established market presence and customer base [1]

证券日报网讯超研股份8月22日在互动平台回答投资者提问时表示，公司在定期报告中披露对应时点的 股东人数信息。 （文章来源：证券日报） ...

Core Insights - The Chinese AI + medical imaging industry is rapidly developing, with a market size projected to reach 7.6 billion yuan in 2024, representing a year-on-year growth of 109.94% [1][11] - AI technology is capable of quickly identifying small lesions from vast amounts of imaging data, facilitating precise early screening for various diseases and providing significant diagnostic support for doctors [1][11] - The product types in AI medical imaging are diversifying, with a trend towards integrated hardware and software solutions becoming the preferred choice for medical institutions [1][11] Industry Overview - AI + medical imaging refers to the use of AI technologies, such as deep learning and computer vision, to analyze and process medical images (e.g., X-rays, CT scans, MRIs, ultrasounds) to assist doctors in disease diagnosis, treatment planning, and prognosis evaluation [1][4] - The core function includes auxiliary diagnosis, treatment planning, prognosis assessment, and early detection screening [1][4] Industry Value Chain - The upstream of the AI + medical imaging industry includes medical imaging equipment, chips, servers, storage devices, imaging acquisition and processing software, cloud services, network operation platforms, and algorithm and data platforms [4] - The midstream involves the development and manufacturing of AI + medical imaging technologies, while the downstream primarily serves medical institutions, health check centers, and research and educational institutions [4] Market Size - The market size of the Chinese medical imaging equipment industry is expected to reach 69.3 billion yuan in 2024, with a year-on-year growth of 9.83% [6] Relevant Policies - The Chinese government has issued several policy documents to support and regulate the development of the AI + medical imaging industry, emphasizing the optimization of medical device standards and the establishment of standardization organizations for AI and medical robotics [8][10] - The policies aim to accelerate approval processes, enhance innovation ecosystems, and improve international competitiveness [8][10] Key Companies and Performance - Major companies in the AI + medical imaging sector include United Imaging Healthcare, Wandong Medical, Mindray, and Shukun Technology, each leveraging unique strengths in hardware and AI software integration [13][15] - United Imaging Healthcare reported a revenue of 10.3 billion yuan in 2024, a decrease of 9.73% year-on-year, while its R&D investment increased by 17.84% to 2.261 billion yuan [15] - Shukun Technology focuses on providing comprehensive AI solutions for medical institutions, achieving significant market penetration with its innovative products [17] Industry Development Trends 1. The industry is expected to advance towards multi-modal data integration and deep learning, enhancing diagnostic accuracy and personalized treatment [20] 2. Applications of AI in medical imaging will expand from auxiliary diagnosis to full-process management, improving service efficiency and quality [21] 3. Regulatory frameworks will evolve to include data privacy protections and accountability mechanisms for AI-generated content [22]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise focusing on medical imaging and industrial non-destructive testing equipment [7]. - The company's main business revenue composition includes: medical ultrasound 50.32%, industrial ultrasound 19.04%, X-ray 16.30%, accessories 12.52%, and others 1.82% [7]. Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 98.43 million yuan, representing a year-on-year growth of 28.69%, and a net profit attributable to the parent company of 39.32 million yuan, with a year-on-year increase of 47.70% [8]. - As of March 31, 2025, the company had 26,800 shareholders, a decrease of 46.67% from the previous period, with an average of 2,047 circulating shares per person, an increase of 87.50% [8]. Market Activity - On August 20, the company's stock price increased by 0.11%, with a trading volume of 212 million yuan and a turnover rate of 12.93%, resulting in a total market capitalization of 12.087 billion yuan [1]. - The main net inflow of funds today was 8.9166 million yuan, accounting for 0.04%, with the industry ranking at 9 out of 131 [4]. Product and Technology Development - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual meeting, focusing on pet, equine, and livestock health care [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR equipment, enabling remote transmission of images and reports through 5G networks, and offers online diagnostic guidance through the "Mali Doctor" platform [2][3].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and medical device sectors, benefiting from the depreciation of the RMB and its recent listing as a new stock under the registration system [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The main business revenue composition includes: medical ultrasound 50.32%, industrial ultrasound 19.04%, X-ray 16.30%, accessories 12.52%, and others 1.82% [7]. Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 98.43 million, representing a year-on-year growth of 28.69%, and a net profit attributable to the parent company of 39.32 million, with a year-on-year increase of 47.70% [8]. - As of March 31, 2025, the company had a total of 26,800 shareholders, a decrease of 46.67% from the previous period, with an average of 2,047 circulating shares per person, an increase of 87.50% [8]. Market Activity - On August 18, the company's stock rose by 2.16%, with a trading volume of 240 million and a turnover rate of 14.56%, bringing the total market capitalization to 12.177 billion [1]. - The stock has seen a net outflow of 17.76 million from major investors today, with a continuous three-day trend of being reduced by major funds [4][5]. Product and Technology Development - The company showcased its innovative veterinary medical imaging achievements at the 97th WVC annual conference, focusing on pet, equine, and livestock health care [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices that utilizes 5G networks for remote image transmission and interaction, enhancing the development of portable devices [2][3].